Ventyx Biosciences, Inc. (NASDAQ:VTYX) Given Average Rating of “Reduce” by Brokerages

Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) have earned a consensus rating of “Reduce” from the nine research firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and eight have issued a hold rating on the company. The average 1 year target price among brokers that have covered the stock in the last year is $14.00.

VTYX has been the subject of several recent research reports. HC Wainwright cut Ventyx Biosciences from a “buy” rating to a “neutral” rating and set a $14.00 price objective for the company. in a report on Thursday, January 8th. Oppenheimer downgraded shares of Ventyx Biosciences from an “outperform” rating to a “market perform” rating in a research note on Thursday, January 8th. Piper Sandler lowered shares of Ventyx Biosciences from an “overweight” rating to a “hold” rating and set a $14.00 price objective on the stock. in a report on Thursday, January 8th. Clear Str cut shares of Ventyx Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, January 7th. Finally, Wall Street Zen raised shares of Ventyx Biosciences to a “hold” rating in a report on Saturday, March 7th.

Ventyx Biosciences Price Performance

Shares of Ventyx Biosciences stock opened at $14.00 on Thursday. The firm has a market cap of $1.00 billion, a P/E ratio of -9.33 and a beta of 1.26. Ventyx Biosciences has a fifty-two week low of $0.78 and a fifty-two week high of $25.00. The firm has a 50 day simple moving average of $13.86 and a 200 day simple moving average of $8.98.

Insider Buying and Selling at Ventyx Biosciences

In other Ventyx Biosciences news, insider John Nuss sold 12,675 shares of the stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $7.72, for a total value of $97,851.00. Following the transaction, the insider owned 489,481 shares of the company’s stock, valued at approximately $3,778,793.32. This represents a 2.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Raju Mohan sold 47,345 shares of the firm’s stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $7.72, for a total value of $365,503.40. Following the transaction, the chief executive officer owned 2,372,863 shares in the company, valued at approximately $18,318,502.36. This trade represents a 1.96% decrease in their position. The disclosure for this sale is available in the SEC filing. 14.49% of the stock is owned by company insiders.

Institutional Trading of Ventyx Biosciences

Institutional investors and hedge funds have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Ventyx Biosciences in the 4th quarter valued at approximately $31,000. State of Wyoming acquired a new position in Ventyx Biosciences during the fourth quarter valued at approximately $101,000. Orion Porfolio Solutions LLC acquired a new position in Ventyx Biosciences during the fourth quarter valued at approximately $103,000. Entropy Technologies LP bought a new stake in Ventyx Biosciences in the fourth quarter valued at approximately $105,000. Finally, Rafferty Asset Management LLC bought a new stake in Ventyx Biosciences in the fourth quarter valued at approximately $123,000. 97.88% of the stock is owned by institutional investors.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.